This session reviews optimizing use of the newest pharmacotherapeutic options for slowing progression of kidney disease and managing anemia of chronic kidney disease. Successful avoidance and risks of drug-induced nephrotoxicity and acute injury from medications also will be discussed.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 10/16/2025.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):
Planning Committee Disclosures: There are no Planning Committee disclosures to declare.
Commercial Support: No commercial support declared.
Accreditation Statement: The American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 17499.
ANNA urges participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this learning activity, the participant will be able to confidently articulate optimal use of newer pharmacologic agents to slow chronic kidney disease and manage common comorbidities in this complex patient population